Lupin Q1 FY24 Growth Metrics and ESG Goals
North America: Gaining Momentum
Growing Respiratory
portfolio
Leadership: Delivering 5.2%
TRX Gx volume of the U.S.1
New product sales driving
US growth ($ mn)
DE
177
159
175
181
R
#3
#1
21.8%
in the US1
in 41 products²
Albuterol
market share
Maintaining
leadership
Top 3 in 109
products²
Q2FY23
Q3FY23
49% YoY
Q4FY23 Q1FY24
3% QoQ
In generics
•
Q1 FY24 Key Highlights
Continued focus on profitable growth
Continued strength in Q1FY24 with FTF
gDarunavir launch and gSpiriva approval
USFDA Inspections: Successful Nagpur OSD
inspection and EIR for Pithampur Unit 2
Note:
1.
IQVIA Qtr Gx Jun-23 by prescriptions
2.
IQVIA Qtr Mar-23 NSP data
LUPIN
41.0%
Arfomoterol
market share
Brand + generic
•
Evolving Complex Product Portfolio through
investments in Injectables and Inhalation
Current pipeline includes 54 FTFs incl. 21
exclusive FTFs
Substantial investments in Inhalation, Injectables
and Biosimilars pipeline and capabilities
(Development and Manufacturing)
30+ strong pipeline of Injectables and 22+ strong
inhalation pipeline
7View entire presentation